JP6891183B2 - ラパフシン・ライブラリの合成と組成物 - Google Patents
ラパフシン・ライブラリの合成と組成物 Download PDFInfo
- Publication number
- JP6891183B2 JP6891183B2 JP2018540102A JP2018540102A JP6891183B2 JP 6891183 B2 JP6891183 B2 JP 6891183B2 JP 2018540102 A JP2018540102 A JP 2018540102A JP 2018540102 A JP2018540102 A JP 2018540102A JP 6891183 B2 JP6891183 B2 JP 6891183B2
- Authority
- JP
- Japan
- Prior art keywords
- rapafcin
- library
- synthesis
- composition
- viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003786 synthesis reaction Methods 0.000 title description 4
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000012636 effector Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 8
- 229960002930 sirolimus Drugs 0.000 description 8
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- FPGXOHHWOLBEGI-HXUWFJFHSA-N CC(C)(C)C(COc1cccc([C@@H](CCc2ccc(C)c(OC)c2)O)c1)=O Chemical compound CC(C)(C)C(COc1cccc([C@@H](CCc2ccc(C)c(OC)c2)O)c1)=O FPGXOHHWOLBEGI-HXUWFJFHSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N CC(C)(C)OC(CBr)=O Chemical compound CC(C)(C)OC(CBr)=O BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- ALZNWMXUAQSCSA-UHFFFAOYSA-N CC(C)(C)OC(COc1cc(C(CCc(cc2OC)ccc2OC)=O)ccc1)=O Chemical compound CC(C)(C)OC(COc1cc(C(CCc(cc2OC)ccc2OC)=O)ccc1)=O ALZNWMXUAQSCSA-UHFFFAOYSA-N 0.000 description 1
- FMQIDODVYIXOCY-DPRQTADFSA-N CC(C)(C)OC(COc1cc([C@@H](CCc2ccc(C)c(OC)c2)OC([C@H](CCCC2)N2C(C(C(C)(C)COC(C=C)=O)=O)=O)=O)ccc1)O Chemical compound CC(C)(C)OC(COc1cc([C@@H](CCc2ccc(C)c(OC)c2)OC([C@H](CCCC2)N2C(C(C(C)(C)COC(C=C)=O)=O)=O)=O)ccc1)O FMQIDODVYIXOCY-DPRQTADFSA-N 0.000 description 1
- MJAVVYWNSTURBG-JTQLQIEISA-N CC(C)(COC(C=C)=O)C(C(N(CCCC1)[C@@H]1C(O)=O)=O)=O Chemical compound CC(C)(COC(C=C)=O)C(C(N(CCCC1)[C@@H]1C(O)=O)=O)=O MJAVVYWNSTURBG-JTQLQIEISA-N 0.000 description 1
- AYPUVXGSXSKEGZ-IZZNHLLZSA-N CC(C)(COC(C=C)=O)C(C(N(CCCC1)[C@@H]1C(O[C@H](CCc(cc1OC)ccc1OC)c1cccc(OCC(O)=O)c1)=O)=O)=O Chemical compound CC(C)(COC(C=C)=O)C(C(N(CCCC1)[C@@H]1C(O[C@H](CCc(cc1OC)ccc1OC)c1cccc(OCC(O)=O)c1)=O)=O)=O AYPUVXGSXSKEGZ-IZZNHLLZSA-N 0.000 description 1
- LUJMEECXHPYQOF-UHFFFAOYSA-N CC(c1cccc(O)c1)=O Chemical compound CC(c1cccc(O)c1)=O LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 1
- SUALBXZCVIZQQY-CMDGGOBGSA-N Cc(ccc(/C=C/C(c1cccc(O)c1)=O)c1)c1OC Chemical compound Cc(ccc(/C=C/C(c1cccc(O)c1)=O)c1)c1OC SUALBXZCVIZQQY-CMDGGOBGSA-N 0.000 description 1
- TVDHPUFLDYYBPO-UHFFFAOYSA-N Cc1ccc(C=O)cc1OC Chemical compound Cc1ccc(C=O)cc1OC TVDHPUFLDYYBPO-UHFFFAOYSA-N 0.000 description 1
- KVHOEZPZFZYAQX-UHFFFAOYSA-N Cc1ccc(CCC(c2cccc(O)c2)=O)cc1OC Chemical compound Cc1ccc(CCC(c2cccc(O)c2)=O)cc1OC KVHOEZPZFZYAQX-UHFFFAOYSA-N 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
本発明は、国立衛生研究所(National Institutes of Health)の助成金 DP1CA174428 に基づく政府の支援によってなされた。米国政府は本発明に一定の権利を有する。
以下の参考文献は、本明細書に援用され、その全体が本明細書に組み込まれる。
1) US 2014/0073581
Claims (5)
- 式(I)の化合物:
又は、薬学的に許容されるその塩若しくは溶媒和物であって、ここで:
R は、
である、
R 1 , R 4 , 及び R 5 はそれぞれ水素である、R 2 及び R 3 はそれぞれメトキシである;
m = 0;
X1 は、O 若しくは NR 6 である、
Yは、
である、
X 2 は、 O 若しくは NR 6 C(O)である;
R 6 は、水素若しくはアルキルである;
Z は
である;
L 1 は、 -CH 2 -C(O)- 若しくは -(CH 2 ) 2 C(O)-である;
L 2 は、 -OCO-CH=CH-(CH 2 ) 2 N(Me)-である;
L 3 は、 -CH 2 CH 2 - である;並びに、
前記エフェクター・ドメインは式(VIII)の構造を有する
-AA 1 -AA 2- AA 3 -AA 4 - (VIII)
ここで、AA 1 , AA 2 , AA 3 及び AA 4 は、それぞれ独立して、以下から選択される:
- X2 が O、及び L1 が -CH2-C(O)- である、請求項1に記載の化合物。
- X2 が NR6C(O)、及び L1 が -(CH2)2C(O)- である、請求項1に記載の化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021088242A JP7158532B2 (ja) | 2016-02-04 | 2021-05-26 | ラパフシン・ライブラリの合成と組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291437P | 2016-02-04 | 2016-02-04 | |
US62/291,437 | 2016-02-04 | ||
PCT/US2017/016481 WO2017136708A1 (en) | 2016-02-04 | 2017-02-03 | Synthesis and composition of rapafucin libraries |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021088242A Division JP7158532B2 (ja) | 2016-02-04 | 2021-05-26 | ラパフシン・ライブラリの合成と組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019510738A JP2019510738A (ja) | 2019-04-18 |
JP2019510738A5 JP2019510738A5 (ja) | 2020-02-06 |
JP6891183B2 true JP6891183B2 (ja) | 2021-06-18 |
Family
ID=59501078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018540102A Active JP6891183B2 (ja) | 2016-02-04 | 2017-02-03 | ラパフシン・ライブラリの合成と組成物 |
JP2021088242A Active JP7158532B2 (ja) | 2016-02-04 | 2021-05-26 | ラパフシン・ライブラリの合成と組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021088242A Active JP7158532B2 (ja) | 2016-02-04 | 2021-05-26 | ラパフシン・ライブラリの合成と組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10662220B2 (ja) |
EP (1) | EP3411413A4 (ja) |
JP (2) | JP6891183B2 (ja) |
CN (1) | CN108713028B (ja) |
AU (1) | AU2017214550B2 (ja) |
CA (1) | CA3013589A1 (ja) |
MX (1) | MX2018009405A (ja) |
WO (1) | WO2017136708A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021138726A (ja) * | 2016-02-04 | 2021-09-16 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ラパフシン・ライブラリの合成と組成物 |
US11555054B2 (en) | 2016-02-04 | 2023-01-17 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
US11708391B2 (en) | 2016-02-04 | 2023-07-25 | The Johns Hopkins University | Rapaglutins, novel inhibitors of GLUT and use thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6294080B2 (ja) | 2011-12-28 | 2018-03-14 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
CN118256591A (zh) * | 2017-06-09 | 2024-06-28 | 中外制药株式会社 | 膜透过性高的环状肽化合物及包含其的文库 |
TW202126323A (zh) | 2019-10-01 | 2021-07-16 | 約翰斯赫普金斯大學 | 雷帕弗辛(Rapafucin)衍生化合物及其使用方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798355A (en) * | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
CN1187127A (zh) * | 1995-06-07 | 1998-07-08 | 吉尔福特药品有限公司 | 旋转异构酶活性抑制剂 |
US7056935B2 (en) | 1995-06-07 | 2006-06-06 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
JP2002503667A (ja) * | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US20080306098A1 (en) | 2006-11-06 | 2008-12-11 | Mutz Mitchell W | Pharmacokinetics of protease inhibitors and other drugs |
EP2313419A1 (en) * | 2008-06-17 | 2011-04-27 | Biotica Technology Limited | Novel compounds and methods for their production |
CA2819501C (en) | 2010-11-30 | 2020-03-31 | The Johns Hopkins University | Hybrid cyclic libraries and screens thereof |
EP2607352A1 (en) | 2011-12-22 | 2013-06-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pipecolate-diketoamides for treatment of psychiatric disorders |
EP3007696B1 (en) * | 2013-06-14 | 2019-10-16 | The Board of Regents of The University of Texas System | Novel allosteric inhibitors of proteasome and methods of use thereof |
EP3411413A4 (en) | 2016-02-04 | 2019-09-18 | The Johns Hopkins University | SYNTHESIS AND COMPOSITION OF RAPAFUCINE LIBRARIES |
-
2017
- 2017-02-03 EP EP17748264.3A patent/EP3411413A4/en active Pending
- 2017-02-03 US US16/074,017 patent/US10662220B2/en active Active
- 2017-02-03 WO PCT/US2017/016481 patent/WO2017136708A1/en active Application Filing
- 2017-02-03 CA CA3013589A patent/CA3013589A1/en not_active Abandoned
- 2017-02-03 MX MX2018009405A patent/MX2018009405A/es unknown
- 2017-02-03 JP JP2018540102A patent/JP6891183B2/ja active Active
- 2017-02-03 AU AU2017214550A patent/AU2017214550B2/en active Active
- 2017-02-03 CN CN201780010182.2A patent/CN108713028B/zh active Active
-
2021
- 2021-05-26 JP JP2021088242A patent/JP7158532B2/ja active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021138726A (ja) * | 2016-02-04 | 2021-09-16 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ラパフシン・ライブラリの合成と組成物 |
JP7158532B2 (ja) | 2016-02-04 | 2022-10-21 | ザ・ジョンズ・ホプキンス・ユニバーシティ | ラパフシン・ライブラリの合成と組成物 |
US11555054B2 (en) | 2016-02-04 | 2023-01-17 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
US11708391B2 (en) | 2016-02-04 | 2023-07-25 | The Johns Hopkins University | Rapaglutins, novel inhibitors of GLUT and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108713028B (zh) | 2021-12-28 |
JP7158532B2 (ja) | 2022-10-21 |
JP2019510738A (ja) | 2019-04-18 |
AU2017214550A1 (en) | 2018-08-16 |
WO2017136708A1 (en) | 2017-08-10 |
US20190092808A1 (en) | 2019-03-28 |
AU2017214550B2 (en) | 2024-03-07 |
EP3411413A4 (en) | 2019-09-18 |
JP2021138726A (ja) | 2021-09-16 |
EP3411413A1 (en) | 2018-12-12 |
CA3013589A1 (en) | 2017-08-10 |
US10662220B2 (en) | 2020-05-26 |
CN108713028A (zh) | 2018-10-26 |
MX2018009405A (es) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6891183B2 (ja) | ラパフシン・ライブラリの合成と組成物 | |
Milroy et al. | Modulators of protein–protein interactions | |
US20210255167A1 (en) | Compositions and methods for assessing toxicity using dynamic bh3 profiling | |
Gembitsky et al. | A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation | |
JP2018516844A (ja) | ペプチド模倣大環状分子およびその使用 | |
Habeshian et al. | Synthesis and direct assay of large macrocycle diversities by combinatorial late-stage modification at picomole scale | |
EP1751300A2 (en) | T-cell death-inducing epitopes | |
Calvo et al. | Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site | |
KR20100074743A (ko) | 초고속 스크리닝용 단백질칩 시스템을 이용한 항체모방 펩타이드 탐색방법 | |
EP3640642A1 (en) | Novel artificial phospholipid-protein bioconjugates for biomolecular recognition | |
CN1671859A (zh) | 从复杂混合物中鉴定出单一活性实体的方法 | |
Beeston et al. | Validation of ion mobility spectrometry‐mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase | |
JP4496168B2 (ja) | 非特異的物質の除去方法 | |
WO2020262617A1 (ja) | 細胞融合促進剤 | |
JP2023517939A (ja) | オーロラaキナーゼの分解のためのタンパク質分解誘導キメラ分子(protac) | |
CN107158002B (zh) | 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用 | |
Essig et al. | Development of Peptide-Based PDZ Domain Inhibitors | |
Belcher | Chemoproteomic Strategies for Drug Discovery and Natural Product Target Identification | |
Soini | Identification of molecular glues of 14-3-3 Protein-Protein Interactions | |
Knott | Development of Mass Spectrometry-Based Proteomic Approaches for the Study of Diseased Tissues | |
JP4491419B2 (ja) | 非特異的物質の除去方法 | |
Torrini et al. | Bioactive fMLF‐OMe analogs containing a N‐terminal oximic or formylhydrazonic moiety | |
Kubiniok | Time-Resolved Phosphoproteomics Unravel the Dynamics of Intracellular Signaling | |
West | Systematic evaluation and tuning of diazirine chemistry used in photoaffinity labeling | |
WO2024137034A1 (en) | Cyclosporine-acridinium esters and methods of production and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210427 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210526 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6891183 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |